A new form of drug drastically improves survival rates of younger women with the most common type of breast cancer, researchers said on Saturday, citing the results of an international clinical trial.
The findings, presented at the annual meeting of the American Society of Clinical Oncology in Chicago, showed that the addition of cell-cycle inhibitor ribociclib increased survival rates to 70 percent after three-and-a-half years.
The mortality rate was 29 percent less than when patients, all under 59 and pre-menopausal, were randomly assigned a placebo.
Lead author Sara Hurvitz said the study focused on a form of breast cancer that is fueled by the hormone estrogen and which accounts for two-thirds of all cases among younger women.
It is generally treated by therapies that block the hormone’s production.
“You actually can get synergy, or a better response, better cancer kill, by adding one of these cell-cycle inhibitors” on top of the hormone blocking therapy, Hurvitz said.
The drug works by inhibiting the activity of cancer-cell promoting enzymes. The treatment is less toxic than traditional chemotherapy, because it more selectively targets cancerous cells, blocking their ability to multiply.
Though advanced breast cancer is less common among younger women, its incidence grew 2 percent per year in the US between 1978 and 2008 for women aged 20 to 39, a previous study showed.
The new trial, which looked at more than 670 cases, included only women who had advanced cancer — stage four — for which they had not received prior hormone-blocking therapy.
“These are patients who tend to be diagnosed later, at a later stage in their disease, because we don’t have great screening modalities for young women,” Hurvitz said.
In addition, patients who develop breast cancer early tend to have more complex cases.
A pill is administered daily for 21 days followed by seven days off to allow the body time to recover, since two-thirds of patients have a moderate to severe drop in white cell count.
Jamie Bennett, a spokeswoman for Novartis, which markets the drug under the brand name Kisqali and funded the research, said it cost US$12,553 for a 28-day dose.
There is no cure for metastatic breast cancer and the majority of the women on the drug will require some form of therapy for the rest of their lives.
Oncologist Harold Burstein of the Dana-Farber Cancer Institute in Boston, who was not involved in the research, said it was “an important study,” having established that the use of the drug “translates into a significant survival benefit for women.”
“Hopefully, these data will enable access for this product for more women around the world, particularly in healthcare systems which assess value rigorously as part of their decisions for national access to drugs,” Burstein added.
Drug lord Jose Adolfo Macias Villamar, alias “Fito,” was Ecuador’s most-wanted fugitive before his arrest on Wednesday, more than a year after he escaped prison from where he commanded the country’s leading criminal gang. The former taxi driver turned crime boss became the prime target of law enforcement early last year after escaping from a prison in the southwestern port of Guayaquil. Ecuadoran President Daniel Noboa’s government released “wanted” posters with images of his face and offered US$1 million for information leading to his capture. In a country plagued by crime, members of Fito’s gang, Los Choneros, have responded with violence, using car
Two former Chilean ministers are among four candidates competing this weekend for the presidential nomination of the left ahead of November elections dominated by rising levels of violent crime. More than 15 million voters are eligible to choose today between former minister of labor Jeannette Jara, former minister of the interior Carolina Toha and two members of parliament, Gonzalo Winter and Jaime Mulet, to represent the left against a resurgent right. The primary is open to members of the parties within Chilean President Gabriel Boric’s ruling left-wing coalition and other voters who are not affiliated with specific parties. A recent poll by the
TENSIONS HIGH: For more than half a year, students have organized protests around the country, while the Serbian presaident said they are part of a foreign plot About 140,000 protesters rallied in Belgrade, the largest turnout over the past few months, as student-led demonstrations mount pressure on the populist government to call early elections. The rally was one of the largest in more than half a year student-led actions, which began in November last year after the roof of a train station collapsed in the northern city of Novi Sad, killing 16 people — a tragedy widely blamed on entrenched corruption. On Saturday, a sea of protesters filled Belgrade’s largest square and poured into several surrounding streets. The independent protest monitor Archive of Public Gatherings estimated the
Irish-language rap group Kneecap on Saturday gave an impassioned performance for tens of thousands of fans at the Glastonbury Festival despite criticism by British politicians and a terror charge for one of the trio. Liam Og O hAnnaidh, who performs under the stage name Mo Chara, has been charged under the UK’s Terrorism Act with supporting a proscribed organization for allegedly waving a Hezbollah flag at a concert in London in November last year. The rapper, who was charged under the anglicized version of his name, Liam O’Hanna, is on unconditional bail before a further court hearing in August. “Glastonbury,
RSS